Wyeth extends collaboration with Curis

Wyeth has agreed to extend the research term by one year to February 9, 2007. Curis expects Wyeth to select a development candidate in the next twelve to eighteen months, and to file an investigational new drug (IND) application approximately twelve months thereafter.

“We are encouraged by the continued dedication that Wyeth has shown to the Hedgehog agonist program for neurological disorders. The extension of funding for the program serves as a validation of the progress made to date on this program, and we look forward to working with Wyeth to select a development candidate for stroke and other neurological disorders,” said Daniel Passeri, president and CEO of Curis.

In January 2004, Curis entered into the collaboration agreement with Wyeth. Under the terms of the collaboration, Wyeth paid Curis an up-front license fee and is obligated to provide two years of research funding and recently extended its funding for an additional year. In addition, if clinical development of any hedgehog agonist technology-based products is successful, Wyeth is obligated to pay Curis clinical milestone payments and royalties on product sales.